Altay Therapeutics has closed a $37 million Series A financing to push DX5057, an oral small-molecule inhibitor of the transcription factor DUX4, toward its first clinical trial in facioscapulohumeral muscular dystrophy (FSHD). The San Francisco company announced the round on 14 October 2026, co-led by Sound Bioventures and HealthCap, roughly a year after a rival oral candidate from Fulcrum Therapeutics failed its own pivotal trial in the same rare, currently untreatable muscle disease.
Altay's Series A, in four figures
Figures from Altay Therapeutics' 14 October 2026 Series A announcement, as reported via Fountain Healthcare Partners, HealthCap and Sound Bioventures.
A disease with no drug to modify it
Facioscapulohumeral muscular dystrophy progressively weakens the face, shoulder and upper-arm muscles, and roughly one in five patients eventually loses the ability to walk. US prevalence estimates vary widely across sources — from roughly 1 in 8,000 to 1 in 15,000 by some counts, to NORD's figure of 4 to 10 cases per 100,000 — but every estimate describes a population with no FDA-approved disease-modifying treatment. That gap got starker in September 2024, when Fulcrum Therapeutics reported that losmapimod, an oral drug working through a different mechanism, failed to improve reachable workspace versus placebo in its 260-patient Phase 3 REACH trial; the company's CEO said it planned to suspend the program.
How big a category Altay is entering
$34.2M vs. $600M
Two 2025 estimates of the FSHD drug market across major markets (the US, EU4, UK and Japan), from IMARC Group and DelveInsight — a roughly 18x gap reflecting different scope and methodology.
Sources: IMARC Group, Facioscapulohumeral Muscular Dystrophy Market report · DelveInsight, Facioscapulohumeral Muscular Dystrophy Market Insight, Epidemiology and Market Forecast - 2034
Regulatory News outlook
We expect the category's size to stay contested until a disease-modifying therapy actually reaches approval, since today's wide gap between published estimates reflects a market still defined by symptom management rather than any approved drug's real sales.
How we got here: Applying DelveInsight's own published ~15% compound annual growth rate to its $600 million 2025 baseline projects a category of roughly $2.8 billion by 2036 if that growth rate holds — a figure DelveInsight has not itself published and that this article has calculated from its stated inputs, not a number we are attributing to the publisher.
DX5057 against the FSHD field it would join
| Candidate | Mechanism | Route | Status |
|---|---|---|---|
| DX5057 (Altay Therapeutics) | Small-molecule DUX4 inhibitor | Oral | Preclinical; Phase 1 planned Q1 2027; FDA Orphan Drug Designation |
| Losmapimod (Fulcrum Therapeutics) | p38α/β MAPK inhibitor | Oral | Phase 3 REACH failed primary endpoint, Sep 2024; program reported suspended |
| Delpacibart braxlosiran / del-brax, AOC 1020 (Avidity Biosciences, acquired by Novartis) | Antibody-oligonucleotide conjugate, reduces DUX4-driven gene expression | Intravenous infusion | Phase 1/2 FORTITUDE ongoing; Novartis completed acquisition of Avidity, Feb 2026 |
From each company's own announcements and trial disclosures; not a clinical comparison. DX5057 has not yet entered human trials, so no clinical data exists to compare against the other two candidates' own readouts.
Shutting down DUX4 instead of working around it
DUX4 is a transcription factor normally active only briefly in very early embryonic development, then silenced for life. In FSHD, a genetic change relaxes that silencing in skeletal muscle, letting DUX4 switch back on and, researchers believe, trigger a toxic gene-expression program that kills muscle cells over time. Rather than targeting a downstream consequence of that process the way losmapimod's anti-inflammatory mechanism did, Altay says DX5057 is designed to inhibit DUX4 itself, systemically, from an oral dose — the same upstream target Avidity's infused antibody-oligonucleotide conjugate works through by a different chemistry.
Three things Altay is betting the round on
A pill, not an infusion
Avidity's rival DUX4 program is delivered intravenously; Altay is betting that a systemic oral small molecule, if it works, would be easier for patients to take and easier for the company to manufacture and distribute.
Upstream of the failed drug
Losmapimod targeted inflammatory signaling downstream of DUX4 reactivation and failed its Phase 3; DX5057 targets DUX4 directly, a mechanistically different bet in the same disease.
Patient-advocacy money, then venture money
SOLVE FSHD's roughly $7 million in seed backing since 2022, with a board seat, funded the preclinical work that then attracted six institutional investors to this Series A.
“DX5057 is an oral medicine that acts systemically to shut down DUX4 at its source.” James Breitmeyer, M.D., Ph.D., Chief Executive Officer, Altay Therapeutics — 14 October 2026 Series A announcement
From a father-and-son lab to six new investors
Altay's road to a Phase 1 trial
- 2019
Altay Therapeutics founded
Co-founded by Ali Ozes and his father, Osman Ozes, incubated at MBC BioLabs in San Carlos, California, around a drug-discovery platform for transcription-factor targets.
- 2022
SOLVE FSHD begins seed investment
The FSHD-focused venture-philanthropy organization starts a roughly $7 million seed commitment and takes a board-level role, backing Altay's early DUX4-inhibitor discovery work.
- September 2024
A rival oral candidate fails
Fulcrum Therapeutics' losmapimod misses its Phase 3 primary endpoint in FSHD; the company says it plans to suspend the program, leaving the oral-therapy field open.
- Early 2026
James Breitmeyer joins as CEO
Breitmeyer, M.D., Ph.D., becomes Chief Executive Officer and a board director, ahead of the company's institutional fundraise.
- 14 October 2026
$37 million Series A closes
Sound Bioventures and HealthCap co-lead the round; four new directors join Altay's board.
- Q1 2027
Phase 1 safety study planned
Altay expects to begin DX5057's first human trial, ahead of a Phase 2 proof-of-concept study in FSHD patients.
What the round does not resolve: DX5057 has not yet been dosed in a human being, and its preclinical results — however encouraging to six institutional investors — are not evidence of safety or efficacy in FSHD patients. Fulcrum's experience is the cautionary case directly in front of Altay: a mechanistically plausible oral drug that worked in earlier-stage studies and still failed at Phase 3. Whether an upstream, direct DUX4 inhibitor fares differently will not be known until Altay's own Phase 1 and Phase 2 data arrive, starting with the safety study the company says is still several months from its first patient.
Sources & further reading
- Fountain Healthcare Partners, "Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic," 14 October 2026. fh-partners.com
- HealthCap, "Altay Therapeutics Closes $37 Million Series A Financing to Advance First Oral DUX4 Inhibitor for FSHD into the Clinic," 14 October 2026. healthcap.eu
- Global Genes RARE Daily, "Altay Raises $37 Million to Advance Oral Drug for Inherited Muscle Disease," October 2026. globalgenes.org
- BioSpace, "SOLVE FSHD invests US$3 million in Altay Therapeutics," 2022. biospace.com
- Fulcrum Therapeutics, topline Phase 3 REACH trial results for losmapimod in FSHD, 12 September 2024, as reported by BioPharmaWatch. biopharmawatch.com
- IMARC Group, Facioscapulohumeral Muscular Dystrophy Market report. imarcgroup.com
- DelveInsight, Facioscapulohumeral Muscular Dystrophy Market Insight, Epidemiology and Market Forecast - 2034. delveinsight.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What is DX5057 meant to do?
It is an investigational oral small molecule designed to inhibit DUX4, a transcription factor that is normally silenced after early embryonic development but becomes abnormally reactivated in the muscle cells of people with facioscapulohumeral muscular dystrophy (FSHD), where it is believed to drive muscle-cell death. Altay describes DX5057 as acting systemically, taken as a pill rather than requiring an infusion or injection. These are preclinical findings; safety and efficacy in people have not yet been established.
Is there an approved treatment for FSHD today?
No disease-modifying therapy is currently FDA-approved for FSHD; treatment is limited to managing symptoms. Fulcrum Therapeutics' oral candidate losmapimod, which worked through a different mechanism, failed to meet its primary endpoint in a Phase 3 trial reported in September 2024, and the company said it planned to suspend the program.
Who funded the Series A, and what does it pay for?
The $37 million round was co-led by Sound Bioventures and HealthCap, with participation from Fountain Healthcare Partners, Biogen New Ventures, Pappas Capital and Global BioAccess Fund. Altay says the proceeds will fund a Phase 1 safety study, expected to start in the first quarter of 2027, followed by a Phase 2 proof-of-concept trial in people with FSHD.
Had Altay raised money before this round?
Yes. SOLVE FSHD, a venture-philanthropy organization focused on the disease, invested roughly $7 million in seed financing in Altay since 2022 and has held a board-level role; that early backing is separate from, and smaller than, this Series A.
